SUNGSAM MEDICAL FOUNDATION – Trademark Portfolio
Entity Type: 12
SUNGSAM MEDICAL FOUNDATION holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 3 filings in this category. The portfolio also extends into Class 36 (Insurance & Financial) across 3 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include M and M MIZMEDI HOSPITAL. The owner is based in Seoul.
295, Gangseo-ro, Gangseo-gu
Seoul 07639 , KR
Showing of trademarks Trademarks
Trademark Classifications
SUNGSAM MEDICAL FOUNDATION's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Insurance; financial affairs; monetary affairs; real estate affairs
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Frequently Asked Questions
How many trademarks does SUNGSAM MEDICAL FOUNDATION have?
SUNGSAM MEDICAL FOUNDATION has 3 U.S. trademarks filed with the USPTO. Of these, 3 registered.
What trademark classes does SUNGSAM MEDICAL FOUNDATION file in?
SUNGSAM MEDICAL FOUNDATION files trademarks across 3 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 36 (Insurance & Financial), Class 44 (Medical Services). Class 42 covers scientific and technological services; industrial analysis and research services.
What are SUNGSAM MEDICAL FOUNDATION's most well-known trademarks?
SUNGSAM MEDICAL FOUNDATION's registered trademark portfolio includes well-known marks such as M and M MIZMEDI HOSPITAL. These are among 3 currently registered trademarks in the portfolio.
What is SUNGSAM MEDICAL FOUNDATION's trademark registration success rate?
SUNGSAM MEDICAL FOUNDATION has a 100% trademark registration rate, with 3 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.